Effects of orlistat therapy on plasma concentrations of oxygenated and hydrocarbon carotenoids.
Orlistat is a lipase inhibitor that is applied for treating obesity. Lipases are required for digestion and absorption of dietary lipids and fat-soluble vitamins and carotenoids. The aim of this study was to compare the effects of orlistat therapy on plasma concentrations of oxygenated (beta-cryptoxanthin, lutein/zeaxanthin) and hydrocarbon (alpha-, beta-carotene, lycopene) carotenoids. Six patients with a body mass index (BMI) > or = 30 kg/m2 received 360 mg/d orlistat over 4.5 mon. Plasma carotenoid concentrations were determined at baseline (T0) and after 3 (T3) and 4.5 mon (T4.5) along with anthropometric, dietary, and biochemical indices, including plasma lipids, retinol, (alpha- and gamma-tocopherols, and FA. Baseline BMI was 32.7 +/- 1.97 kg/m2. Five of six patients lost weight; the average weight loss was 3.6 +/- 2.4% (P = 0.47). There were no significant changes in dietary carotenoid intakes. In contrast, plasma alpha- and beta-carotene concentrations decreased significantly from T0 to T4.5 by 45% (P = 0.006) and 32% (P = 0.013), respectively. Plasma lycopene decreased from T0 to T3 but increased again from T3 to T4.5, while beta-cryptoxanthin and lutein/zeaxanthin concentrations did not change. There were no significant alterations in tocopherol, retinol, and FA concentrations. In conclusion, even though weight loss was not significant, orlistat therapy was associated with significant decreases in plasma concentrations of the highly lipophilic hydrocarbon carotenoids, alpha- and beta-carotene.
Sundl
Isabella
I
Human Nutrition & Metabolism Research and Training Center Graz, Institute of Molecular Biosciences, Karl-Franzens University, 8010 Graz, Austria.
Pail
Elisabeth
E
Mellitzer
Karin
K
Toplak
Hermann
H
Winklhofer-Roob
Brigitte M
BM
D000368:Aged; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002338:Carotenoids / Q000097:blood*; D065366:Cryptoxanthins; D005260:Female; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D014975:Lutein / Q000097:blood; D000077276:Lycopene; D008297:Male; D008875:Middle Aged; D000077403:Orlistat; D024341:Xanthophylls / Q000097:blood; D065146:Zeaxanthins; D019207:beta Carotene / Q000097:blood
D019440:Anti-Obesity Agents; D065366:Cryptoxanthins; D007783:Lactones; D024341:Xanthophylls; D065146:Zeaxanthins; D019207:beta Carotene; D002338:Carotenoids; C041635:alpha-carotene; D000077403:Orlistat; D000077276:Lycopene; D014975:Lutein
Clin Chem. 1972 Jun;18(6):499-502
4337382
Methods Enzymol. 1999;299:348-62
9916214
JAMA. 1999 Jan 20;281(3):235-42
9918478
J Clin Pharmacol. 1996 Jul;36(7):647-53
8844448
Annu Rev Nutr. 1993;13:561-87
8369159
Free Radic Biol Med. 1995 May;18(5):849-59
7797092
JAMA. 1999 Oct 27;282(16):1523-9
10546691
Anal Biochem. 1991 Oct;198(1):184-90
1838668
JAMA. 2003 Jan 1;289(1):76-9
12503980
Diabetes Obes Metab. 2002 Jan;4(1):49-55
11874442
Clin Pharmacol Ther. 1999 Sep;66(3):315-22
10511068
Am J Clin Nutr. 2002 Jul;76(1):172-9
12081831
J Clin Pharmacol. 1994 Nov;34(11):1121-5
7876405
Am J Clin Nutr. 1996 Oct;64(4):622-6
8839509
Clin Chem. 1997 Jan;43(1):146-53
8990237
Am J Epidemiol. 2002 Jun 1;155(11):1023-32
12034581
Pharmacotherapy. 2002 Jul;22(7):814-22
12126214
Obes Rev. 2003 Feb;4(1):25-42
12608525
Am J Clin Nutr. 1995 Dec;62(6 Suppl):1427S-1430S
7495243
Lancet. 1998 Jul 18;352(9123):167-72
9683204
Eur J Clin Pharmacol. 1998 Apr;54(2):125-32
9626916
Pharmacotherapy. 2000 Mar;20(3):270-9
10730683
Annu Rev Nutr. 2002;22:483-504
12055355
Int J Obes Relat Metab Disord. 2001 Nov;25(11):1713-21
11753595
Atherosclerosis. 1999 May;144(1):117-22
10381285
Am J Clin Nutr. 1999 Aug;70(2):261-8
10426704
J Nutr. 2005 Jun;135(6):1456-61
15930452